Development
Sarepta Therapeutics, Inc.
SRPT
$16.88
-$0.2196-1.28%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 396.78M | 331.82M | 261.24M | 253.50M | 258.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 396.78M | 331.82M | 261.24M | 253.50M | 258.43M |
| Cost of Revenue | 239.69M | 231.33M | 276.01M | 280.70M | 244.60M |
| Gross Profit | 157.09M | 100.49M | -14.78M | -27.20M | 13.82M |
| SG&A Expenses | 131.70M | 120.89M | 118.56M | 110.71M | 120.48M |
| Depreciation & Amortization | 763.00K | 439.00K | 179.00K | 178.00K | 179.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 372.16M | 352.66M | 394.76M | 391.59M | 365.26M |
| Operating Income | 24.63M | -20.84M | -133.52M | -138.09M | -106.83M |
| Income Before Tax | 40.37M | -33.17M | -14.59M | -512.71M | -101.31M |
| Income Tax Expenses | -5.28M | 7.76M | 9.36M | 4.05M | 7.94M |
| Earnings from Continuing Operations | 45.66M | -40.94M | -23.94M | -516.76M | -109.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.66M | -40.94M | -23.94M | -516.76M | -109.24M |
| EBIT | 24.63M | -20.84M | -133.52M | -138.09M | -106.83M |
| EBITDA | 36.00M | -9.91M | -122.73M | -126.78M | -96.28M |
| EPS Basic | 0.49 | -0.46 | -0.27 | -5.86 | -1.24 |
| Normalized Basic EPS | 0.19 | -0.12 | -0.91 | -0.96 | -0.70 |
| EPS Diluted | 0.43 | -0.46 | -0.27 | -5.86 | -1.24 |
| Normalized Diluted EPS | 0.16 | -0.12 | -0.91 | -0.96 | -0.70 |
| Average Basic Shares Outstanding | 93.62M | 88.89M | 88.74M | 88.19M | 87.84M |
| Average Diluted Shares Outstanding | 105.59M | 88.89M | 88.74M | 88.19M | 87.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |